Location of Repository

Suppression of humoral immune response to hepatitis B surface antigen vaccine in BALB/c mice by 1-methyl-tryptophan co-administration

By T Sparopoulou, T Eleftheriadis, G Antoniadi, V Liakopoulos, I Stefanidis and G Galaktidou

Abstract

  Background and the purpose of the study:Indoleamine 2,3-dioxygenase (IDO) suppresses adaptive immune response. The purpose of this study was to determine the effect of the IDO inhibitor namely 1-methyl-DL-tryptophan (DL-1-MT) on antibody production after vaccination with hepatitis B surface (HBs) antigen. Methods:Four groups of BALB/c mice were immunized with a HBs antigen vaccine. In the first group the vaccine had no DL-1-MT, whereas in the other three groups the vaccine contained 1 mg , 10 mg and 20 mg DL-1-MT. Blood samples were collected 5 weeks post-vaccination and anti-HBs antibodies in the serum were measured by ELISA. Results:Compared to the three groups of mice that were immunized with the vaccines containing DL-1-MT, serum anti-HBs level was much higher in the mice that were immunized with the vaccine with out DL-1-MT. Conclusions:Inhibition of IDO at the time of vaccination decreased humoral immune response to HBs antigen vaccine. The idea that IDO activity is simply immunosuppressive may need to be re-evaluated

Topics: DL-1-MT, IDO, Serum anti-HBs, Therapeutics. Pharmacology, RM1-950, Medicine, R, DOAJ:Therapeutics, DOAJ:Medicine (General), DOAJ:Health Sciences, Pharmacy and materia medica, RS1-441, DOAJ:Pharmacy and materia medica
Publisher: BioMed Central
Year: 2011
OAI identifier: oai:doaj.org/article:2f7b2a6030c0424f82fd05a2cf348051
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1560-8115 (external link)
  • http://journals.tums.ac.ir/Pdf... (external link)
  • https://doaj.org/article/2f7b2... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.